Viatris Inc. Common Stock (VTRS)
Stock · NASDAQ · Health Care
$18.66as of 10/16/2026
Price chart
Active signals
VTRS Signal Track Record
How signals performed across all stocks →What VTRS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +0.7% | 54% | September 18, 2026 |
| Bollinger Band BreakoutActive now | 28 | +3.1% | 71% | September 25, 2026 |
| Bollinger Band Breakdown | 19 | -3.0% | 37% | June 18, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +3.6% | 73% | September 17, 2025 |
| Any 20-session window (baseline) | +1.4% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 30,000
- Website
- www.viatris.com/en
Fundamentals
- 1-day range
- $17.33$17.66
- Market cap
- $18.97B
- P/E (trailing)
- —
- P/E (forward)
- 6.54
- EPS (trailing)
- $-0.36
- Dividend yield
- 5.09%
- Beta
- 0.89
- Avg. volume
- 9.29M
- Ex-dividend date
- August 21, 2026
- Dividend pay date
- September 16, 2026
How Viatris Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Viatris Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VTRSViatris Inc. Common Stock$18.66▲ 2.41%Market cap $18.97BP/E —$9.73$18.43
- JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$210.23▼ 1.95%Market cap $16.66BP/E 14.90$128.8$266.38
- BBIOBridgeBio Pharma Inc. Common Stock$66.39▼ 1.10%Market cap $16.20BP/E —$52.75$93.42
- ASNDAscendis Pharma A/S Ordinary Share$225.25▼ 0.60%Market cap $15.49BP/E 16.93$186.05$282.15
- UTHRUnited Therapeutics Corporation Common Stock$533.12▼ 1.55%Market cap $22.62BP/E 17.78$409.07$609.35
- ROIVRoivant Sciences Ltd. Common Shares$33.53▼ 1.50%Market cap $25.38BP/E —$15.9$42.5
- ARWRArrowhead Pharmaceuticals Inc. Common Stock$55.9▼ 4.44%Market cap $12.12BP/E —$36.02$95.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VTRS Viatris Inc. Common Stock | $18.97B | — | $18.66 | ▲ 2.41% | $9.73$18.43 |
| JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland) | $16.66B | 14.90 | $210.23 | ▼ 1.95% | $128.8$266.38 |
| BBIO BridgeBio Pharma Inc. Common Stock | $16.20B | — | $66.39 | ▼ 1.10% | $52.75$93.42 |
| ASND Ascendis Pharma A/S Ordinary Share | $15.49B | 16.93 | $225.25 | ▼ 0.60% | $186.05$282.15 |
| UTHR United Therapeutics Corporation Common Stock | $22.62B | 17.78 | $533.12 | ▼ 1.55% | $409.07$609.35 |
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $33.53 | ▼ 1.50% | $15.9$42.5 |
| ARWR Arrowhead Pharmaceuticals Inc. Common Stock | $12.12B | — | $55.9 | ▼ 4.44% | $36.02$95.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adultsbenzinga · 10/16/2026
- Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell RightsYahoo · 10/10/2026
- Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC SaysYahoo · 10/9/2026
- Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen BankruptcyBenzinga · 10/9/2026
- Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioYahoo · 10/9/2026
- How Your Taxes Will Be Different Next Year, And Why You'll Have Trump To ThankBenzinga · 10/9/2026
- Viatris To Acquire Pacira BioSciences: What Investors Should KnowSeekingAlpha · 10/9/2026
- Buy Any Of 15 Ideal 'Safer' October Dogs Tenured Over 10 YearsSeekingAlpha · 10/9/2026
- Viatris (VTRS) Buys Pacira As Fair Value Stays In FocusYahoo · 10/9/2026
Insider Activity
Insider Actions →- Leo Frans Groothuis · September 30, 2026 · Grant2.5K @ $17.72
- David S. Simmons · September 30, 2026 · Grant2.1K @ $17.72
- Andrew Enrietti · August 15, 2026 · Option Exercise998
- Andrew Enrietti · August 15, 2026 · Option Exercise25.1K
- Andrew Enrietti · August 15, 2026 · Tax Withholding435 @ $16.23
- Andrew Enrietti · August 15, 2026 · Option Exercise999
- Andrew Enrietti · August 15, 2026 · Tax Withholding10.9K @ $16.23
- Leo Frans Groothuis · June 30, 2026 · Grant2.8K @ $15.88
- David S. Simmons · June 30, 2026 · Grant2.4K @ $15.88
- Paul Campbell · June 25, 2026 · Sale50.1K @ $16.17
- Goff Corinne Le · April 15, 2026 · Option Exercise39.3K
- Goff Corinne Le · April 15, 2026 · Tax Withholding1.6K @ $13.86
- Goff Corinne Le · April 15, 2026 · Tax Withholding17.4K @ $13.86
- Goff Corinne Le · April 15, 2026 · Option Exercise3.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 930.93M
- Total value held
- $11.29B
- Institutional holders
- 1004
- Unknown84.36M
- Unknown78.21M
- Unknown74.72M
- Unknown65.86M
- Unknown52.23M
- Unknown38.31M
- Unknown33.50M
- Unknown31.85M
- Unknown21.97M
- Unknown20.21M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal
Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.